用于临床应用的间充质干细胞。
Mesenchymal stem cells for clinical application.
机构信息
Etablissement Français du Sang-GECSoM, Tours cedex 3, France.
出版信息
Vox Sang. 2010 Feb;98(2):93-107. doi: 10.1111/j.1423-0410.2009.01227.x. Epub 2009 Aug 3.
Mesenchymal Stem Cells/Multipotent Marrow Stromal Cells (MSC) are multipotent adult stem cells present in all tissues, as part of the perivascular population. As multipotent cells, MSCs can differentiate into different tissues originating from mesoderm ranging from bone and cartilage, to cardiac muscle. Conflicting data show that MSCs could be pluripotent and able to differentiate into tissues and cells of non-mesodermic origin as neurons or epithelial cells. Moreover, MSCs exhibit non-HLA restricted immunosuppressive properties. This wide range of properties leads to increasing uses of MSC for immunomodulation or tissue repair. Based on their immunosuppressive properties MSC are used particularly in the treatment of graft versus host disease, For tissue repair, MSCs can work by different ways from cell replacement to paracrine effects through the release of cytokines and to regulation of immune/inflammatory responses. In regenerative medicine, trials are in progress or planed for healing/repair of different tissue or organs as bone, cartilage, vessels, myocardium, or epithelia. Although it has been demonstrated that ex-vivo expansion processes using fetal bovine serum, recombinant growth factors (e.g. FGF2) or platelet lysate are feasible, definitive standards to produce clinical-grade MSC are still lacking. MSCs have to be produced according GMP and regulation constraints. For answering to the numerous challenges in this fast developing field of biology and medicine, integrative networks linking together research teams, cell therapy laboratories and clinical teams are needed.
间充质干细胞/多能骨髓基质细胞(MSC)是存在于所有组织中的多能成体干细胞,作为血管周围群体的一部分。作为多能细胞,MSC 可以分化为不同的组织,这些组织来源于中胚层,包括骨骼和软骨,以及心肌。相互矛盾的数据表明,MSC 可能具有多能性,能够分化为非中胚层起源的组织和细胞,如神经元或上皮细胞。此外,MSC 表现出非 HLA 限制的免疫抑制特性。这种广泛的特性导致 MSC 在免疫调节或组织修复方面的应用越来越多。基于其免疫抑制特性,MSC 特别用于治疗移植物抗宿主病。对于组织修复,MSC 可以通过不同的方式发挥作用,从细胞替代到通过释放细胞因子和调节免疫/炎症反应的旁分泌作用。在再生医学中,正在进行或计划用于治疗不同组织或器官的试验,如骨骼、软骨、血管、心肌或上皮组织。尽管已经证明使用胎牛血清、重组生长因子(如 FGF2)或血小板裂解物进行体外扩增过程是可行的,但生产临床级 MSC 的明确标准仍然缺乏。MSC 必须按照 GMP 和监管要求进行生产。为了应对这个快速发展的生物学和医学领域中的众多挑战,需要整合研究团队、细胞治疗实验室和临床团队的网络。